Description

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-anti-virus–C85H121N23O20S2—Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Sci Total Environ. 2024 Mar 13:171681.-[1]1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.|[2]Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215.|[3]Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450.—-1849.16–99.93–CC(O)=O.CN1C2=CC=CC=C2C(C[C@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)C)=O)NC([C@H]([C@@H](C)CC)NC([C@H](N)CC4=CC=C(C=C4)O)=O)=O)C(N(C)[C@H](C(N)=O)[C@@H](C)CC)=O)=O)CCCNC(N)=N)=O)CC5=CN=CN5)=O)C)=O)C)=O)CC6=CNC7=CC=CC=C67)=O)CC(O)=O)=O)CCC(N)=O)=O)=C1–Inflammation/Immunology–DMSO : 100 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)–Complement System;SARS-CoV—-Anti-infection;Immunology/Inflammation–Peptides